FDA Approves Apellis' Syfovre as First Treatment for Geographic Atrophy

On Friday, the FDA approved Apellis Pharmaceuticals' Syfovre (pegcetacoplan) as the first treatment for geographic atrophy (GA), a leading cause of blindness.

GA causes areas of the retinal cells to waste away and die in some patients with age-related macular degeneration. The condition affects over five million worldwide and, until now, progressed relentlessly without any treatments to slow the decline in patient’s vision.